[1]刘 鑫,张 锦,袁东红,等.复生康胶囊联合高强度聚焦超声消融术治疗胃癌肝转移临床研究*[J].陕西中医,2020,(2):164-167.
　LIU Xin,ZHANG Jin,YUAN Donghong,et al.Fushengkang capsules combined high intensity focused ultrasound ablation in the treatment of gastric cancer with liver metastases[J].,2020,(2):164-167.
点击复制

复生康胶囊联合高强度聚焦超声消融术治疗胃癌肝转移临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年2期
页码:
164-167
栏目:
临床研究
出版日期:
2020-02-05

文章信息/Info

Title:
Fushengkang capsules combined high intensity focused ultrasound ablation in the treatment of gastric cancer with liver metastases
文章编号:
DOI:〖HT5K〗10.3969/j.issn.10007369.2020.02.007
作者:
刘 鑫; 张 锦; 袁东红; 孟存英; 谭玉娥△
延安大学附属医院消化内科(延安 716000)
Author(s):
LIU Xin; ZHANG Jin; YUAN Donghong; et al.
Department of Gastroenterology,Affiliated Hospital of Yan'an University(Yan'an 716000)
关键词:
胃癌肝转移;  复生康胶囊;  高强度聚焦超声消融术;  免疫功能;  肝功能;  生存时间
Keywords:
Gastric cancer with liver metastases;  Fushengkang capsules;  High intensity focused ultrasound ablation;  Immune function;  Liver function;  Survival time
分类号:
R735.2
文献标志码:
A
摘要:
目的:探讨复生康胶囊联合高强度聚焦超声消融术(HIFUA)治疗不可切除的胃癌肝转移的临床治疗效果。方法:运用随机数字表法将226例不可切除的胃癌肝转移患者分为观察组和对照组,各113例。两组均采用HIFUA进行治疗,观察组另给予复生康胶囊,而对照组则给予安慰剂。治疗前后,检测两组患者免疫功能指标,主要包括IgG、IgA、IgM、CD3+及CD4+水平; 检测两组患者肿瘤标记物含量,主要包括AFU、GP73、CA242及Frr; 检测两组患者肝功能指标,主要包括TBIL、AST、ALP及ALT。治疗后,对两组进行为期3年的随访,分别比较两组患者的1年和3年生存率、PFS和OS。结果:治疗后,观察组IgG、IgA、IgM、CD3+及CD4+均显著高于对照组(P<0.05),而AFU、GP73、CA242及Frr含量均显著低于对照组,且TBIL、AST、ALP及ALT含量亦均显著低于对照组(P<0.05)。相较于对照组,观察组患者的1年和3年生存率、PFS及OS均显著升高,且差异具有统计学意义(P<0.05)。结论:复生康胶囊联合HIFUA可有效改善不可切除的胃癌肝转移患者的免疫和肝功能,延长患者的生存时间。
Abstract:
Objective:To observe the clinical study of Fushengkang capsules combined high intensity focused ultrasound ablation(HIFUA)in the treatment of unresectable gastric cancer with liver metastases.Methods:A total of 226 patients with unresectable gastric cancer with liver metastases were divided into the observation group and the control group by random number table method,113 cases in each group.The 2 groups were treated by HIFUA,and the observation group and the control group were given Fushengkang capsules and placebo,respectively.Before and after treatment,the immune index(IgG,IgA,IgM,CD3+ and CD4+),tumor markers(AFU,GP73,CA242 and Frr),liver function indexs(TBIL,AST,ALP and ALT)of the 2 groups were detected.After the treatment,3 years follow-up were performed in the 2 groups,and the 1 year survival rate,3 years survival rate,PFS and OS of the 2 groups were compared.Results:After the treatment,the levels of IgG,IgA,IgM,CD3+ and CD4+ in the observation group were significantly higher than those in the control group(P<0.05),AFU,GP73,CA242 and Frr were significantly lower than those in the control group(P<0.05),moreover TBIL,AST,ALP and ALT levels were also significantly lower than those in the control group(P<0.05).Compared with the control group,the 1-year and 3-year survival rates,PFS and OS in the observation group were significantly increased,and the difference was statistically significant(P<0.05).Conclusion:Fushengkang capsules combined HIFUA in the treatment of unresectable gastric cancer with liver metastases can effectively promote the immune and liver function,prolong the survival time of patients.

参考文献/References:

[1] 朱信强,管文贤.胃癌肝转移的综合治疗 [J].现代肿瘤医学,2017,25(5):829-833.
[2] 任丽楠,曲 虹.胃癌肝转移治疗现状 [J].中国临床实用医学,2016,7(3):1-2.
[3] 徐宏智,曾家耀,吴 卫.胃癌肝转移的外科治疗研究新进展 [J].中国普通外科杂志,2016,25(10):1500-1505.
[4] 孙 佳,卢 洁,林 萍.胃癌肝转移的治疗研究进展 [J].临床合理用药杂志,2017,10(25):174-175.
[5] 陈 凛,李佶阳.胃癌肝转移的外科综合治疗 [J].外科理论与实践,2015,20(1):9-14.
[6] 肖元元,赵华新,赵 瑜,等.高强度聚焦超声对恶性肿瘤患者血浆D-二聚体的影响 [J].现代肿瘤医学,2015,23(7):989-991.
[7] 中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范 [M].2版.北京:北京医科大学中国协和医科大学联合出版社,1996:16.
[8] 俞泽元,周辉年,郭凌云,等.胃癌肝转移的治愈性手术切除 [J].中华消化外科杂志,2016,15(2):197-199.
[9] 王 博.改良XELOX方案对胃癌伴肝转移的治疗效果观察 [J].中国现代药物应用,2017,11(8):61-62.
[10] 郭 峰,杨维秀.原发性胃癌手术后肝脏转移的相关因素研究 [J].中国现代普通外科进展,2016,19(5):369-371.
[11] 冷家骅,武爱文.胃癌肝转移的外科治疗 [J].中国肿瘤外科杂志,2017,9(1):1-4.
[12] 唐家伟,严 飞,李叶阔,等.高强度聚焦超声联合纳米颗粒在肿瘤治疗中的研究进展 [J].中国医学影像学杂志,2016,24(5):388-391.
[13] 李 非,罗 曼,李发琪,等.高强度聚焦超声治疗中热波效应和声热耦合研究进展 [J].中国医学物理学杂志,2016,33(5):442-444.
[14] 陈 飞,马大钊,邹建中.高强度聚焦超声增效的方法学研究进展 [J].中国医学影像技术,2016,32(10):1597-1600.
[15] 谢之微,杨婉花,金润麟,等.替吉奥联合奥沙利铂治疗中晚期胃癌并发肝转移临床疗效及安全性研究[J].陕西医学杂志,2018,47(2):235-237.
[16] 黄瑞松,叶云峰,苏 青,等.复生康胶囊质量标准的研究 [J].中草药,2003,34(8):698-701.
[17] 公培强,肖 琴,沈元良,等.蒿芩清胆汤联合高强度聚焦超声治疗胆囊癌肝转移疗效及其对患者血清免疫球蛋白含量的影响 [J].中华中医药学刊,2017,35(11):2831-2835.
[18] 张卫星,黄 耀,邓卫萍.高强度聚焦超声治疗中晚期肝癌后早期肝功能变化观察 [J].临床和实验医学杂志,2007,6(7):25-26.
[19] 祁向争,马志豪,李志强.中医药改善胃癌前病变炎症因子研究进展[J].陕西中医,2019,40(7):976-978.

备注/Memo

备注/Memo:
*陕西省教育厅自然科学研究项目(2013JK0782)
更新日期/Last Update: 2020-03-31